News 2025-05-23
Porton to Showcase Integrated CDMO Expertise at BOS Basel 2025
BOS Basel 2025, a premier
global event for biopharmaceutical outsourcing, will convene industry leaders
to address critical challenges in CMC outsourcing for Small Molecules,
Biologics, and Novel Therapeutic Entities. Since its inception in Sheffield
(2006), BOS Events have evolved into a refined platform featuring four key
components, including a dynamic exhibition highlighting innovations from CROs
and CMOs worldwide. (Note: Information sourced from the BOS official
website.)
Porton Pharma Solutions, a global CDMO with over 4,200 employees and GMP facilities
across the US, EU, and China, will demonstrate its end-to-end capabilities in
Small Molecules, Tides, Biologics, Conjugates (ADCs, AOCs, PDCs, etc.), and
Advanced Therapy Medicinal Products (ATMPs) at Booth #62. Our customer-centric solutions span preclinical
development to commercial manufacturing, supported by state-of-the-art
technology platforms and proven expertise in complex modalities.
Engaging with our scientists and business leaders at Booth #62 to share the latest industry insights and discuss future challenges. Schedule a personalized meeting via our website to explore how we can accelerate your program’s success.
Others
More
News 2026-10-24
Porton Shared Complex Bioconjugate Development Strategies at the 17th World ADC San Diego
As a conference partner, Porton contributed a scientific presentation and poster addressing the technical challenges of developing ADCs and emerging bioconjugates.

News 2026-10-22
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.